Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study
Brussels: International Diabetes Federation (2021)
Therapeutic potential of semaglutide, a newer GLP1 receptor agonist, in abating obesity, nonalcoholic steatohepatitis and neurodegenerative diseases: a narrative review
We provide evidence that this targeting concept can be used to antagonize NMDA receptors specifically in GLP-1-receptor-positive neurons to reverse obesity and correct symptoms of cardiometabolic diseases in preclinical obesity models
Compounded semaglutide and tirzepatide are different: they are prepared by a licensed compounding pharmacy and dispensed only with a valid prescription after a medical evaluation
Furthermore, companies are engaging in partnerships with research institutions and universities to improve product offerings